[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353368-105":59,"doc-detail-353368-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-igf2bp3-in-cancer-from-molecular-structure-and-biology-to-early-drug-discovery","Targeting IGF2BP3 in Cancer - From Molecular Structure and Biology to Early Drug Discovery","","RNA-binding proteins (RBPs) are increasingly recognized as viable small-molecule targets, since their dysregulation contributes to multiple human diseases, especially cancer. RBPs control post-transcriptional gene expression across RNA transcription, processing, transport, stability, and translation. Among them, IGF2BP3 is an oncofetal RBP strongly expressed during embryogenesis, largely absent in adult tissues, and re-expressed in many malignancies. The review assesses IGF2BP3 as a biomarker and oncogenic driver, and outlines structural, mechanistic, and emerging therapeutic strategies for early drug discovery.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-igf2bp3-in-cancer-from-molecular-structure-and-biology-to-early-drug-discovery/353368/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-igf2bp3-in-cancer-from-molecular-structure-and-biology-to-early-drug-discovery/353368.png","ImageObject",300,407,{"name":92,"@type":93},"OmBimo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are RNA-binding proteins considered potential small-molecule targets in cancer?","Question",{"text":112,"@type":113},"RBPs regulate post-transcriptional gene expression and their dysregulation is linked to many diseases, including cancer. Their widespread control over RNA metabolism makes them attractive for therapeutic modulation, despite targeting challenges.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What makes IGF2BP3 a focus for cancer research and therapy?",{"text":117,"@type":113},"IGF2BP3 is an oncofetal RBP highly expressed during embryonic development, largely absent in adult tissues, and re-expressed in multiple malignancies. Evidence supports its roles as a diagnostic/prognostic biomarker and as an oncogenic driver across tumor types.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic approaches are discussed for targeting IGF2BP3?",{"text":121,"@type":113},"The review covers direct inhibition of IGF2BP3–RNA interactions and indirect strategies that rewire IGF2BP3 expression or activity. Indirect strategies are described through epigenetic, epitranscriptomic, and signaling pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353368,1790192803,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nTargeting IGF2BP3 in Cancer: From Molecular Structure and Biology to Early Drug Discovery  \nElisa Uliassi 1, Maria Laura Bolognesi 1, Katia Scotlandi 2, * and Caterina Mancarella 2, *  \nAcademic Editor: Elena Dreassi  \nReceived: 5 June 2026  \nRevised: 24 July 2026  \nAccepted: 29 July 2026  \nPublished: 4 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Dipartimento di Farmacia e Biotecnologie, Alma Mater Studiorum–Università di Bologna,  \n40126 Bologna, Italy; [elisa.uliassi3@unibo.it](elisa.uliassi3@unibo.it) (E.U.); [marialaura.bolognesi@unibo.it](marialaura.bolognesi@unibo.it) (M.L.B.)  \n2 Laboratory of Oncology Research and Functional Genomics (ONCOGEN), IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy  \n* Correspondence: [katia.scotlandi@ior.it](katia.scotlandi@ior.it) (K.S.); [caterina.mancarella@ior.it](caterina.mancarella@ior.it) (C.M.); Tel.: +39-051-6366760 (K.S.);+39-051-6366378 (C.M.)  \nAbstract  \nRNA-binding proteins (RBPs) remain underexplored as small-molecule targets, although their dysregulation contributes to numerous human diseases, including cancer. RBPs are key regulators of post-transcriptional gene expression, controlling multiple stages of RNA metabolism. Among them, insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) is an oncofetal RBP that is highly expressed during embryonic development, largely absent in adult tissues, and re-expressed in multiple malignancies. A growing body of evidence supports IGF2BP3 as a diagnostic and prognostic biomarker and a potent oncogenic driver across tumor types, underscoring its potential as a therapeutic target. However, the development of effective IGF2BP3-targeting compounds remains in its early stages. In this review, we first describe the structural organization of IGF2BP3, the molecular basis of RNA recognition, and the mechanisms underlying its dysregulation across human cancers. We then discuss emerging therapeutic approaches, including direct inhibition of IGF2BP3–RNA interactions and indirect strategies that rewire IGF2BP3 expression or activity through epigenetic, epitranscriptomic, and signaling pathways. By critically highlighting the opportunities and limitations of these approaches and their impact on cancer progression, we provide an integrated perspective combining structural biology, medicinal chemistry, and cancer biology to support the development of next-generation IGF2BP3-targeted therapies.  \nKeywords: RNA-binding proteins; IGF2BP3; RNA dynamics; epitranscriptomics; IGF2BP–RNA small molecule inhibitors; BET modulators; natural compounds; rigosertib; trabectedin  \n1. Introduction  \nRNA-binding proteins (RBPs) are critical post-transcriptional regulators of gene expression that control all stages of RNA metabolism—including transcription, splicing, transport, stability, and translation—and contribute to membraneless organelle formation and intracellular signaling networks. Large-scale studies have identified approximately 4200 RBPsin humans, reflecting a remarkable structural and functional diversity [1] . Through their ability to bind both messenger RNAs (mRNAs) and different types of non-coding RNAs, RBPs orchestrate critical physiological processes, tuning cell-fate decisions. Accordingly, dysregulation of RBPs is implicated in numerous diseases, including cancer [1] . Integrated molecular and genomic analyses have led to the identification of at least 16 families of  \nRBPs annotated as oncogenic in human tumors, spanning from leukemia to carcinomasand sarcomas. While biological and molecular studies have provided roadmaps for their mechanisms of action and target genes, RBPs have not been fully explored as candidate targets in cancer therapy. As central post-transcriptional regulators controlling the fate of numerous RNA transcripts, these proteins","cbCaipQ0zFEdDzHl","https://ap.wps.com/l/cbCaipQ0zFEdDzHl","pdf",9101255,32,"English","# Abstract\n# Introduction\n## RNA-binding proteins as regulators of RNA metabolism\n## Challenges and progress in targeting RBPs\n## IGF2BP3 as an oncogenic RNA-network regulator","[{\"question\":\"Why are RNA-binding proteins considered potential small-molecule targets in cancer?\",\"answer\":\"RBPs regulate post-transcriptional gene expression and their dysregulation is linked to many diseases, including cancer. Their widespread control over RNA metabolism makes them attractive for therapeutic modulation, despite targeting challenges.\"},{\"question\":\"What makes IGF2BP3 a focus for cancer research and therapy?\",\"answer\":\"IGF2BP3 is an oncofetal RBP highly expressed during embryonic development, largely absent in adult tissues, and re-expressed in multiple malignancies. Evidence supports its roles as a diagnostic/prognostic biomarker and as an oncogenic driver across tumor types.\"},{\"question\":\"What therapeutic approaches are discussed for targeting IGF2BP3?\",\"answer\":\"The review covers direct inhibition of IGF2BP3–RNA interactions and indirect strategies that rewire IGF2BP3 expression or activity. Indirect strategies are described through epigenetic, epitranscriptomic, and signaling pathways.\"}]","Targeting IGF2BP3 in Cancer - From Molecular Structure and Biology to Early Drug Discovery | PDF",1790104921,81,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c545cabd1bb788204555da0d495d4d0.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c781af6c1e70d69a24ecedd6f3fb85c.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47b663e6079c73d28d8e4d8920002d87.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cda15cf5c1142dbe75725a97ed27f655.webp",980,1385]